Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injections are not licensed for anyone under 18 in the UK. That applies to 16 year olds too. Mounjaro (tirzepatide) and Wegovy (semaglutide) both carry an explicit age restriction in their UK marketing authorisations, meaning no regulated UK prescriber can legally prescribe them to a teenager. This page explains the clinical reasoning behind that, what the evidence shows, and what support options do exist for younger people managing their weight. These are prescription-only medicines; a prescriber decides suitability for every adult patient, and that assessment simply cannot happen for under-18s under the current licence.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The UK marketing authorisations for tirzepatide and semaglutide were granted following large adult clinical trials. SURMOUNT-1, which assessed tirzepatide across 2,539 participants with obesity, enrolled adults only. The same applies to the STEP 1 trial underpinning Wegovy's approval. Regulatory agencies like the MHRA require evidence specific to each age group before they will extend a licence; that paediatric data simply does not yet exist for these medicines at weight-management doses in the UK. Bone development, hormonal change, and growth trajectories in adolescents introduce variables that adult studies cannot address. Until dedicated trials report and the MHRA reviews the findings, no UK prescriber (whether in a GP surgery, a hospital clinic, or an online pharmacy) is authorised to issue a prescription for these medicines to someone aged 16 or 17.
This is not an administrative quirk. It is a patient-safety position grounded in how medicines regulation works. The NHS medicines page for tirzepatide states clearly that it is not for use in under-18s.
Research into GLP-1 medicines for younger age groups is ongoing internationally, and some early results from paediatric semaglutide trials have been published in scientific literature. None of this has translated into a UK licence change. Until the MHRA acts on such evidence, UK clinicians remain bound by the existing authorisations. Elsewhere in the world, semaglutide has received regulatory approval for adolescents in some jurisdictions, but those decisions apply to those regulators only. UK licensing is determined by the MHRA, and that position remains adults only as of summer 2026.
Parents researching options for a 16 year old, or teenagers looking this up for themselves, will encounter plenty of content online that blurs these lines. Some of it describes medicines available in other countries; some describes unlicensed or compounded products with no safety oversight. The MHRA has warned repeatedly about counterfeit and illegally sold weight-loss pens — a risk that is even more acute when the buyer is already excluded from the legitimate supply chain. Reporting suspect sellers via the Yellow Card scheme is genuinely useful if you come across them.
The NHS does have structured pathways for weight management in children and young people. These sit within paediatric and adolescent medicine, typically accessed through a GP who can refer to the right specialist service. NICE guidance on overweight and obesity management covers all age groups; for under-18s, the recommended approaches centre on family-based behavioural programmes, dietary support, physical activity guidance, and where appropriate, specialist clinical review. The starting point is almost always a conversation with a GP, and often the school nurse or a community paediatric dietitian gets involved too. It is not glamorous, and waiting times for specialist services can be frustrating, but it is the evidence-based route for this age group.
You can read more about weight management options and how different approaches compare, or explore the clinical evidence behind different weight loss injections to understand what these medicines do in the adults they are licensed for. The eligibility criteria for weight loss injections covers the full picture of who qualifies, including BMI thresholds and weight-related conditions.
One thing worth knowing if you are a parent or carer reading this: the landscape of weight loss injections in the UK has shifted considerably since 2023, and the information circulating in parent forums is not always accurate. What has not changed is the age restriction. A seller offering these medicines to a 16 year old is acting outside UK law, full stop.
Once someone turns 18 and meets the licensed criteria (broadly a BMI of 30 or above, or 27 or above with a relevant weight-related health condition) they can pursue a private consultation with a regulated UK pharmacy. At that point, the clinical conversation that was previously off-limits becomes possible. A GPhC-registered service will carry out identity verification, weight confirmation, and a full medical review before any prescription is issued. That review is done by a qualified prescriber reading the patient's answers, not automated software.
For anyone approaching 18, it is worth understanding how to find a legitimate provider and what the process looks like, so that when the time comes the decision is an informed one. The cost of weight loss injections is another practical question worth getting clarity on early; prices vary considerably between providers, and what is included in a quoted price matters. Legitimate treatment always involves a prescription and clinical oversight, that is not optional.
If you are newly 18 and would like to discuss whether treatment might be appropriate for you, speaking to our prescribers through a free consultation is the first step. Some adults also ask about whether B12 injections for weight loss might be relevant to them, and our team can help you understand where that fits alongside other options.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.